Gen-Wealth Partners’s AbbVie ABBV Stock Holding History

Gen-Wealth Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$774K	Sell	3,074 -205	-6%	-$44.1K	0.22%	100
2026 Q1	$713K	Sell	3,279 -83	-2%	-$18.4K	0.22%	92
2025 Q4	$768K	Sell	3,362 -904	-21%	-$206K	0.25%	79
2025 Q3	$988K	Buy	4,266 +747	+21%	+$152K	0.33%	70
2025 Q2	$653K	Buy	3,519 +25	+0.7%	+$4.65K	0.25%	103
2025 Q1	$732K	Sell	3,494 -744	-18%	-$145K	0.31%	95
2024 Q4	$753K	Buy	4,238 +19	+0.5%	+$3.49K	0.32%	76
2024 Q3	$850K	Sell	4,219 -25	-0.6%	-$4.67K	0.37%	61
2024 Q2	$728K	Buy	4,244 +321	+8%	+$53.2K	0.35%	63
2024 Q1	$714K	Buy	+3,923	New	+$676K	0.35%	63

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Gen-Wealth Partners's ABBV Position: Q2 2026 in Review

Gen-Wealth Partners reduced its AbbVie (ABBV) stake by 6.3% in Q2 2026, selling an estimated $44.1K and leaving 3,074 shares worth $774K. The position accounts for 0.22% of the portfolio, ranked #100.

Gen-Wealth Partners first reported a position in ABBV in Q1 2024 and has held it in 10 quarters since. The position peaked at $988K in Q3 2025. 4,234 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Gen-Wealth Partners held 3,074 shares of AbbVie worth $774K as of Q2 2026.
Gen-Wealth Partners sold 205 AbbVie shares in Q2 2026, an estimated $44.1K.
AbbVie made up 0.22% of Gen-Wealth Partners's portfolio in Q2 2026, its #100 holding.
Gen-Wealth Partners first reported a position in AbbVie in Q1 2024 and has held it in 10 quarters since.
Gen-Wealth Partners's AbbVie position peaked at $988K in Q3 2025.
4,234 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Gen-Wealth Partners's 13F filing for Q2 2026, filed 10 Aug 2026.